公开(公告)号：US20240252668A1

公开(公告)日：2024-08-01

申请号：US18286664

申请日：2022-04-15

申请人： Anne-Sophie BLUEMMEL ,  Kathrin BUNTIN ,  Joseph Anthony D'ALESSIO ,  Liqiong FAN ,  Boris FESSLER ,  Doris GABRIEL ,  Dominik HAINZL ,  Keith HOFFMASTER ,  Shwetha IYER ,  Eshita KHERA ,  Eusebio Manchado ROBLES ,  Pierre MAUDENS ,  Dominik PISTORIUS ,  Roee RAMOT ,  Vincent ROMANET ,  Kuno WUERSCH ,  Padmaja YERRAMILLI-RAO ,  Novartis AG

发明人： Liqiong Fan ,  Dominik Hainzl ,  Roee Ramot ,  Shwetha Iyer ,  Joseph Anthony D'Alessio ,  Kuno Wuersch ,  Dominik Pistorius ,  Eusebio Manchado Robles ,  Kathrin Buntin ,  Doris Gabriel ,  Boris Fessler ,  Pierre Maudens ,  Vincent Romanet ,  Anne-Sophie Bluemmel ,  Keith Hoffmaster ,  Eshita Khera ,  Padmaja Yerramilli-Rao

IPC分类号： A61K47/68 ,  A61P35/00 ,  C07K11/02 ,  C07K14/47 ,  C07K16/28 ,  C12N9/00 ,  C12N9/02 ,  C12N9/04 ,  C12N9/18 ,  C12N15/52 ,  C12P21/02 ,  C12R1/01 ,  G01N33/574

CPC分类号： A61K47/6849 ,  A61K47/6811 ,  A61K47/6865 ,  A61P35/00 ,  C07K11/02 ,  C07K14/4722 ,  C07K16/28 ,  C12N9/0006 ,  C12N9/0073 ,  C12N9/18 ,  C12N9/93 ,  C12N15/52 ,  C12P21/02 ,  C12Y301/01001 ,  G01N33/57492 ,  C12R2001/01

摘要： This application discloses microorganisms and methods of producing GNAQ/GNA11 inhibitors and methods of making antibody drug conjugates of anti-PMEL17 antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The disclosure also relates to formulations comprising antibody drug conjugates of anti-PMEL 17 antibodies or antigen binding fragments conjugated to a GNAQ/GNA1 inhibitor and methods of treating or preventing cancer using the formulations.

公开(公告)号：US11229643B2

公开(公告)日：2022-01-25

申请号：US16347194

申请日：2017-11-01

申请人： NOVARTIS AG

发明人： Robin Alec Fairhurst ,  Diana Graus Porta ,  Jacqueline Kinyamu-Akunda ,  Andreas Joerg Mahl ,  Luigi Manenti ,  Andreas Weiss ,  Armin Wolf ,  Kuno Wuersch

IPC分类号： A61K31/496 ,  A61K31/14

摘要： The present invention relates to a pharmaceutical combination comprising an FGFR4 inhibitor and a bile acid sequestrant, to the use of the pharmaceutical combination in the treatment of cancer, to the use of a bile acid sequestrant to reduce or mitigate side-effects associated with FGFR4 inhibition therapy.